Commerzbank Aktiengesellschaft Has Lowered Its Position in Chesapeake Energy (CHK) by $368,456; Acadia Pharmaceuticals (ACAD) Holder Longwood Capital Partners Lowered Its Holding as Stock Declined

January 14, 2018 - By Clifton Ray

Longwood Capital Partners Llc decreased its stake in Acadia Pharmaceuticals Inc (ACAD) by 32% based on its latest 2017Q3 regulatory filing with the SEC. Longwood Capital Partners Llc sold 80,000 shares as the company’s stock declined 29.10% while stock markets rallied. The institutional investor held 170,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $6.40M, down from 250,000 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Acadia Pharmaceuticals Inc for a number of months, seems to be less bullish one the $3.52 billion market cap company. The stock increased 1.68% or $0.47 during the last trading session, reaching $28.37. About 1.69M shares traded or 6.52% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since January 14, 2017 and is downtrending. It has underperformed by 31.89% the S&P500.

Commerzbank Aktiengesellschaft decreased its stake in Chesapeake Energy Corp (CHK) by 15.16% based on its latest 2017Q3 regulatory filing with the SEC. Commerzbank Aktiengesellschaft sold 92,114 shares as the company’s stock declined 5.25% while stock markets rallied. The institutional investor held 515,558 shares of the oil & gas production company at the end of 2017Q3, valued at $2.22 million, down from 607,672 at the end of the previous reported quarter. Commerzbank Aktiengesellschaft who had been investing in Chesapeake Energy Corp for a number of months, seems to be less bullish one the $3.83 billion market cap company. The stock increased 2.15% or $0.09 during the last trading session, reaching $4.28. About 33.20 million shares traded or 24.19% up from the average. Chesapeake Energy Corporation (NYSE:CHK) has risen 49.74% since January 14, 2017 and is uptrending. It has outperformed by 33.04% the S&P500.

Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.04, from 1.05 in 2017Q2. It worsened, as 25 investors sold ACAD shares while 58 reduced holdings. 32 funds opened positions while 52 raised stakes. 113.55 million shares or 1.98% less from 115.85 million shares in 2017Q2 were reported. Harvey reported 230,700 shares. California State Teachers Retirement has 155,504 shares for 0.01% of their portfolio. Profund Advsrs Limited Liability Company holds 40,055 shares or 0.06% of its portfolio. Eventide Asset Ltd Company reported 0.71% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Contravisory Invest Management invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Waddell Reed has 0.26% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 3.07M shares. Emory University owns 52,977 shares or 1.58% of their US portfolio. Vanguard invested in 0.01% or 7.77 million shares. Pacad Inv Limited has 3,600 shares. Moreover, Mark Sheptoff Planning Limited Com has 0.01% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Hightower Advsr Lc holds 12,058 shares or 0% of its portfolio. Credit Suisse Ag invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Japan-based Hikari Pwr Limited has invested 0.19% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Palo Alto Investors Limited Liability holds 1.64M shares or 2.6% of its portfolio. Tocqueville Asset LP reported 0.02% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Since August 9, 2017, it had 0 insider purchases, and 5 sales for $5.95 million activity. 25,000 shares were sold by Brege Laura, worth $751,543 on Tuesday, January 2.

Longwood Capital Partners Llc, which manages about $558.01M US Long portfolio, upped its stake in Gogo Inc (Put) (NASDAQ:GOGO) by 85,000 shares to 135,000 shares, valued at $1.59 million in 2017Q3, according to the filing. It also increased its holding in Assembly Biosciences Inc (NASDAQ:ASMB) by 815,000 shares in the quarter, for a total of 1.00M shares, and has risen its stake in Intec Pharma Ltd Jerusalem.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on February, 27. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.53 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 9.43% negative EPS growth.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of ACAD in report on Monday, November 13 with “Buy” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Cowen & Co on Wednesday, October 4. The rating was maintained by J.P. Morgan with “Buy” on Thursday, October 5. Goldman Sachs initiated the stock with “Neutral” rating in Friday, November 11 report. On Thursday, August 27 the stock rating was upgraded by Piper Jaffray to “Neutral”. On Thursday, October 5 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Market Perform” rating by Leerink Swann on Tuesday, May 3. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Friday, September 4 by JP Morgan. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Bank of America on Tuesday, November 8. The firm earned “Buy” rating on Monday, September 4 by Jefferies.

Commerzbank Aktiengesellschaft, which manages about $7.59 billion US Long portfolio, upped its stake in Foot Locker Inc (NYSE:FL) by 59,725 shares to 66,357 shares, valued at $2.34 million in 2017Q3, according to the filing. It also increased its holding in Gilead Sciences Inc (NASDAQ:GILD) by 87,022 shares in the quarter, for a total of 447,753 shares, and has risen its stake in Mccormick & Co Inc (NYSE:MKC).

Among 32 analysts covering Chesapeake Energy Corporation (NYSE:CHK), 7 have Buy rating, 8 Sell and 17 Hold. Therefore 22% are positive. Chesapeake Energy Corporation had 88 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Chesapeake Energy Corporation (NYSE:CHK) earned “Hold” rating by Deutsche Bank on Friday, March 11. UBS maintained the shares of CHK in report on Friday, October 21 with “Sell” rating. The stock of Chesapeake Energy Corporation (NYSE:CHK) has “Hold” rating given on Tuesday, October 10 by BMO Capital Markets. The firm has “Hold” rating by Deutsche Bank given on Tuesday, June 14. The firm has “Buy” rating by SunTrust given on Monday, July 27. On Monday, October 9 the stock rating was downgraded by Jefferies to “Underperform”. Deutsche Bank maintained the shares of CHK in report on Wednesday, December 9 with “Hold” rating. The rating was initiated by Stifel Nicolaus with “Buy” on Thursday, March 23. Piper Jaffray maintained it with “Hold” rating and $6.0 target in Thursday, August 24 report. BMO Capital Markets maintained Chesapeake Energy Corporation (NYSE:CHK) rating on Friday, August 11. BMO Capital Markets has “Hold” rating and $300 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>